FDA could gain new powers next year

11/3/2006 | RPM Report (free registration), The

The FDA could gain several new powers when Congress examines drug safety reforms next year, including greater authority over prescription labels. Other changes could include requiring risk management plans for new drugs, establishing post-market PDUFA goals for safety issues, and clinical trial registration for Phase II, III and IV studies.

View Full Article in:

RPM Report (free registration), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN